RAPT Therapeutics Inc
RAPT7.840USD
+6.810+661.17%
Handelsschluss 06/17, 16:00（ET）Kurse um 15 Minuten verzögert
1.03BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über RAPT Therapeutics Inc Unternehmen
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Unternehmensinformationen
BörsenkürzelRAPT
Name des UnternehmensRAPT Therapeutics Inc
IPO-datumOct 31, 2019
Gegründet am2015
CEODr. Brian Wong, M.D., Ph.D.
Anzahl der mitarbeiter68
WertpapierartOrdinary Share
GeschäftsjahresendeOct 31
Addresse561 Eccles Ave
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16504899000
Websitehttps://rapt.com/
BörsenkürzelRAPT
IPO-datumOct 31, 2019
Gegründet am2015
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
Aktionäre
Aktionäre
Anteil
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
2.96%
Private Equity
2.84%
Hedge Fund
2.64%
Venture Capital
2.25%
Investment Advisor
1.68%
Research Firm
0.08%
Individual Investor
0.06%
Bank and Trust
0.01%
Family Office
0.01%
Other
87.49%
Institutionelle Beteiligung
Aktualisiert: Tue, Mar 4
Aktualisiert: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
301
145.36M
110.11%
+83.62M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
2023Q2
295
35.63M
103.77%
-4.21M
2023Q1
301
34.71M
101.29%
-3.14M
2022Q4
290
33.55M
97.48%
-1.41M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Medicxi Ventures (UK) LLP
22.35M
16.93%
+22.35M
--
Dec 31, 2024
OrbiMed Advisors, LLC
13.14M
9.95%
+13.14M
--
Dec 31, 2024
TCG Crossover Management, LLC
13.14M
9.95%
+13.14M
--
Dec 31, 2024
Foresite Capital Management, LLC
12.50M
9.47%
+12.50M
--
Dec 31, 2024
RTW Investments L.P.
11.76M
8.91%
+11.76M
--
Dec 31, 2024
BVF Partners L.P.
9.24M
7%
+9.24M
--
Dec 31, 2024
The Vanguard Group, Inc.
2.93M
2.22%
-8.95K
-0.30%
Jan 31, 2025
Redmile Group, LLC
6.48M
4.91%
+5.97M
+1.18K%
Dec 31, 2024
Deep Track Capital LP
6.01M
4.55%
+6.01M
--
Dec 31, 2024
Adar1 Capital Management LLC
1.17M
0.89%
+1.17M
+15.56K%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Jun 6
Aktualisiert: Fri, Jun 6
Name
Anteil
Federated Hermes MDT Small Cap Core ETF
0.05%
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
Nuveen ESG Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Humankind US Stock ETF
0%
Invesco Dorsey Wright Healthcare Momentum ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
Mehr Anzeigen
Federated Hermes MDT Small Cap Core ETF
Anteil0.05%
iShares Micro-Cap ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0%
Nuveen ESG Small-Cap ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Humankind US Stock ETF
Anteil0%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil0%
Invesco Nasdaq Biotechnology ETF
Anteil0%
ProShares Ultra Nasdaq Biotechnology
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
